Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

High-yielding dividend stocks may not be the ticket to superior returns, but they can rank pretty high on the list of nice-to ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...

A woman who said the contraceptive jab 'ruined her life' is among one of a number of others experiencing side effects who say ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

Several mRNA vaccine trials found a debilitating side effect, and now the Trump administration is cutting funding for more ...

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Many patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...